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ABSTRACT
BACKGROUND Pulmonary hypertension (PH) is hemodynamically classiﬁed as pre-capillary (as seen in idiopathic
pulmonary arterial hypertension [IPAH]) or post-capillary (as seen in heart failure with preserved ejection fraction
[HFpEF]). Overlaps between these conditions exist. Some patients present with risk factors for left heart disease but pre-
capillary PH, whereas patients with HFpEF may have combined pre- and post-capillary PH.
OBJECTIVES This study sought to further characterize similarities and differences among patient populations with
either PH-HFpEF or IPAH.
METHODS We used registry data to analyze clinical characteristics, hemodynamics, and treatment responses in patients
with typical IPAH (<3 risk factors for left heart disease; n ¼ 421), atypical IPAH ($3 risk factors for left heart disease; n ¼
139), and PH-HFpEF (n ¼ 226) receiving PH-targeted therapy.
RESULTS Compared with typical IPAH, patients with atypical IPAH and PH-HFpEF were older, had a higher body mass
index, had more comorbidities, and had a lower 6-min walking distance, whereas mean pulmonary artery pressure
(46.9  13.3 mm Hg vs. 43.9  10.7 mm Hg vs. 45.7  9.4 mm Hg, respectively) and cardiac index (2.3  0.8 l/min/m2 vs.
2.2  0.8 l/min/m2 vs. 2.2  0.7 l/min/m2, respectively) were comparable among groups. After initiation of targeted
PH therapies, all groups showed improvement in exercise capacity, functional class, and natriuretic peptides from
baseline to 12 months, but treatment effects were less pronounced in patients with PH-HFpEF than typical IPAH; with
atypical IPAH in between. Survival rates at 1, 3, and 5 years were almost identical for the 3 groups.
CONCLUSIONS Patients with atypical IPAH share features of both typical IPAH and PH-HFpEF, suggesting that
there may be a continuum between these conditions. (J Am Coll Cardiol 2016;68:368–78) © 2016 by the American
College of Cardiology Foundation. Published by Elsevier. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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H eart failure with preserved ejection fraction(HFpEF) is frequently accompanied by pul-monary hypertension (PH), which is associ-
ated with a poor outcome. Recent studies have
suggested that PH is found in 36% to 83% of patients
with HFpEF (1–3) and that both elevated pulmonary ar-
tery pressure and right ventricular (RV) dysfunction
are independent predictors of death in patients with
HFpEF (1,4–6).
Hemodynamically, pre-capillary PH—characterized
by a mean pulmonary arterial wedge pressure
(PAWP) #15 mm Hg—is distinguished from post-
capillary PH, as indicated by a PAWP >15 mm Hg
(7–11). The classic example of a disease characterized
by pre-capillary PH is idiopathic pulmonary arterial
hypertension (IPAH), which is caused by an oblitera-
tive pulmonary vasculopathy affecting predomi-
nantly small pulmonary arterioles. In contrast, left
heart disease, such as HFpEF, causes post-capillary
PH due to backward transmission of elevated left-
sided ﬁlling pressures into the pulmonary circulation.
The latter group may present with isolated post-
capillary PH or combined post-capillary PH with a
pre-capillary component, as indicated by an elevated
diastolic pressure gradient and/or an increased
pulmonary vascular resistance (PVR) (8,11,12).
Despite these seemingly clear deﬁnitions, a
growing number of patients with PH are identiﬁed in
whom criteria from multiple PH categories exist
simultaneously. For example, several regis-
tries have documented a change of pheno-
type in patients diagnosed with IPAH,
associated with increasing age (13,14). A sig-
niﬁcant number of these patients have a co-
morbidity proﬁle typically found in patients
with HFpEF, such as arterial hypertension,
obesity, diabetes, and atrial ﬁbrillation (15).
Recently, the terms typical and atypical PAH
have been proposed to distinguish between
these populations (16). The AMBITION
(Ambrisentan and Tadalaﬁl in Patients with
Pulmonary Arterial Hypertension) trial
excluded patients with 3 or more of these risk
factors from the primary analysis set (17).
Although targeted therapies, including
phosphodiesterase type 5 inhibitors (PDE5i),
endothelin receptor antagonists (ERA), and prosta-
cyclin analogues (PCA), are available for IPAH,
evidence-based recommendations for the manage-
ment of PH-HFpEF are lacking and current guidelines
do not support the use of targeted PAH therapies in
patients with PH-HFpEF (8,10,12). Additionally, pa-
tients with atypical IPAH have been under-
represented or excluded in clinical trials.
To further determine similarities and differences
in demographics, comorbidities, hemodynamics,
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AB BR EV I A T I O N S
AND ACRONYM S
ERA = endothelin receptor
antagonist
HFpEF = heart failure with
preserved ejection fraction
IPAH = idiopathic pulmonary
arterial hypertension
PAPm = mean pulmonary
artery pressure
PAWP = pulmonary arterial
wedge pressure
PCA = prostacyclin analogue
PDE5i = phosphodiesterase
type 5 inhibitor
PVR = pulmonary vascular
resistance
TPG = mean transpulmonary
pressure gradient
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treatment responses, and outcomes of patients with
typical or atypical IPAH and patients with PH-HFpEF,
we analyzed data from COMPERA (Comparative,
Prospective Registry of Newly Initiated Therapies for
Pulmonary Hypertension), a European-based PH
registry that enrolls patients with all forms of PH who
receive targeted therapy (13,18).
METHODS
An ongoing, investigator-initiated, noninterventional,
prospective European-based registry, COMPERA is
enrolling consecutive patients with all forms of PH
receiving targeted therapies (NCT01347216). The pre-
sent analysis included data recorded between January
2009 and April 2015 for incident patients (included
into the COMPERA registry within 6 months of PH
diagnosis) ages $18 years. The date of the ﬁrst right
heart catheterization conﬁrming PH was deﬁned as
the date of diagnosis. Documentation included de-
mographics (age, sex, body mass index [BMI], and
comorbidities), type of PH according to the Nice clas-
siﬁcation, World Health Organization functional class
(WHO-FC), 6-min walk distance (6MWD), hemody-
namics, laboratory data, and detailed information
about medications to treat PH. Data were collected
at the time of diagnosis (baseline) and at 6-month
intervals or whenever the patient has a pre-deﬁned
clinical event (death, transplantation, PH-related
hospitalization, deterioration in WHO-FC, any un-
scheduled change in PAH therapy, or other serious
adverse events). Out-of-range data or missing values
were automatically queried during data entry, and
independent onsite monitoring ensured source data
veriﬁcation. This study complies with the Declaration
of Helsinki, the locally appointed ethics committees
approved the research protocol, and informed consent
was obtained from all subjects.
PATIENTS. IPAH was deﬁned by mean pulmonary
artery pressure (PAPm) $25 mm Hg, PAWP #15
mm Hg, and exclusion of other causes of PAH
(Figure 1). Furthermore, patients with IPAH were
subcategorized into typical (<3 risk factors for left
heart disease) or atypical ($3 risk factors for left heart
disease) IPAH on the basis of the criteria used in the
AMBITION trial. The pre-deﬁned risk factors for left
heart disease were arterial hypertension, coronary
artery disease, diabetes, atrial ﬁbrillation, and BMI
>30 kg/m2 at the time of diagnosis (17).
Inclusion criteria for the patients with PH-HFpEF
were a diagnosis of combined post- and pre-capillary
pulmonary hypertension (Cpc-PH) indicated by: 1)
PAPm $25 mm Hg and mean PAWP >15 mm Hg; 2)
preserved left ventricular ejection fraction (>45% by
echocardiography); and 3) presence of echocardio-
graphic signs of diastolic dysfunction of the left
ventricle (corresponding to Nice Group 2.2) (8,19).
Patients with incomplete data regarding their risk
factor proﬁles were excluded from the analysis.
STATISTICAL ANALYSIS. Data are shown as mean 
SD or as median and interquartile range, respectively.
For continuous data, group differences were
compared using the Student t test in case of normal
distribution or by the Mann-Whitney U test other-
wise. Frequency differences were compared using the
chi-square or Fisher exact test. Survival was evalu-
ated with Kaplan-Meier analysis and log-rank test.
Group-wise comparisons were performed with post
hoc adjustment for 3 parallel tests. Predictors of
treatment discontinuation were examined using lo-
gistic regression. With regard to follow-up data, the 3-
month time-point allowed a time window of 15 days
and the 1-year time-point a window of 3 months.
SPSS Statistics version 19.0 (IBM Corp., Armonk, New
York) was used for analysis.
RESULTS
Overall, 5,935 consecutive patients with PH were
enrolled in the COMPERA registry between May 2007
and April 2015. Figure 1 shows the selection of pa-
tients for the present analysis. A total of 786 incident
patients were eligible for the present analysis: 421
with typical IPAH, 139 with atypical IPAH, and 226
with PH-HFpEF. The mean duration of follow-up in
all patients was 24.9  20.1 months, and the median
interval between follow-up documentations was 3.6
months.
Baseline characteristics were different between the
3 groups (Table 1). When compared with typical IPAH,
patients with atypical IPAH as well as those with PH-
HFpEF were signiﬁcantly older, had a higher BMI, and
had a lower 6MWD (all p < 0.001 vs. typical IPAH).
Natriuretic peptide levels were higher in patients
with PH-HFpEF when compared with typical, but not
atypical, IPAH.
By deﬁnition, patients with typical IPAH had fewer
comorbidities at the time of diagnosis. Although
arterial hypertension was present in 43%, the other
risk factors were found in <25% of these patients. In
contrast, 99% of patients with atypical IPAH and 92%
of those with PH-HFpEF had a history of arterial hy-
pertension; all other risk factors were found more
frequently in these groups (p < 0.001 vs. typical IPAH
for all parameters).
HEMODYNAMICS. With respect to hemodynamic
severity of PH, PAPm, cardiac index, and mixed
venous oxygen saturation were comparable in all
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3 groups (Table 1). By deﬁnition, PAWP was higher in
patients with PH-HFpEF, resulting in lower mean
transpulmonary pressure gradient (TPG) and PVR
compared with the other groups. Notably, right atrial
pressure was considerably higher in patients with PH-
HFpEF (13  5 mm Hg) compared with typical IPAH
(9  5 mm Hg; p < 0.001) and atypical IPAH (9  5
mm Hg; p < 0.001).
In the PH-HFpEF group, mean TPG was 26  9
mm Hg, and the vast majority of these patients (201 of
226; 89%) had a TPG >12 mm Hg. Furthermore, mean
PVR was elevated at 7.0  3.4 Wood units (WU),
indicating Cpc-PH (10).
TREATMENT CHARACTERISTICS. As per inclusion
criteria, all patients in the COMPERA registry
received at least 1 targeted PH therapy. However,
the treatment patterns differed signiﬁcantly be-
tween the 3 groups (Table 2): PDE5i were selected
as ﬁrst-line therapy in 77% of the patients with
typical IPAH, in 81% with atypical IPAH, and in
94% with PH-HFpEF. In contrast, ERAs were used
as ﬁrst-line therapy in approximately one-third of
patients with typical IPAH and one-ﬁfth with atyp-
ical IPAH, but in only 7% of the patients with
PH-HFpEF. The use of PCA as ﬁrst-line treatment
was <5% in all groups.
FIGURE 1 Patient Selection
PH-HFpEF
(N = 226)
PAP ≥25 mm Hg,
PAWP >15 mm Hg
“atypical IPAH”
(N = 139)
≥3 risk factors
“typical IPAH”
(N = 421)
<3 risk factors
IPAH (N = 560)
PAP ≥25 mm Hg, PAWP ≤15 mm Hg
excluded (N = 5,149)
non-IPAH PAH (n=1,556)
non-HFpEF PH (n=2,199)
no PH-specific therapy (n=1)
children (n=19)
inclusion before 01.06.2009 (n=330)
prevalent cases (n=462)
inconsistent hemodynamics (n=235)
unclear risk profile (n=347)
•
•
•
•
•
•
•
•
COMPERA cohort
(N = 5,935)
From the original COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension) patients with
pulmonary hypertension (PH), patients were enrolled with PH–heart failure with preserved ejection fraction (HFpEF), or typical or atypical
idiopathic pulmonary arterial hypertension (IPAH) on the basis of the number of risk factors present at PH diagnosis: arterial hypertension,
coronary artery disease, diabetes mellitus, atrial ﬁbrillation, and body mass index >30 kg/m2. PAH ¼ pulmonary arterial hypertension; PAP ¼
pulmonary artery pressure; PAWP ¼ pulmonary artery wedge pressure.
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During follow-up, the preference for PDE5i therapy
in PH-HFpEF persisted (Table 2). At 1 year, 84% of the
typical patients with IPAH received PDE5is, whereas
48% were treated with ERAs and 6% with PCAs. Pa-
tients with atypical IPAH showed similar preference
patterns, but for patients with PH-HFpEF, there was
signiﬁcantly less use of ERAs (p < 0.001 vs. typical
IPAH; p ¼ 0.002 vs. atypical IPAH).
Combination therapy was initiated within 3
months after diagnosis in 18% of the patients with
typical IPAH compared with only 8% of those with
atypical IPAH and 3% of the patients with PH-HFpEF.
At 1 year, combination therapy was used in 44% of the
typical IPAH group, whereas the corresponding
numbers for atypical IPAH and PH-HFpEF were 26%
and 7%, respectively (Table 2).
As shown in Table 3, treatment discontinuation of
PDE5i occurred signiﬁcantly more often in patients
with PH-HFpEF than with typical IPAH (18.4% vs.
8.8%; p¼ 0.005), and patients with atypical IPAHwere
in between at 13%. The main reasons for discontinua-
tion in patients with PH-HFpEF were side effects in
5.3% and lack of efﬁcacy in 10%, the latter being less
frequently observed (<3%) in the other groups.
TABLE 1 Baseline Characteristics
All Patients
(N ¼ 786)
Typical IPAH
(n ¼ 421)
Atypical IPAH
(n ¼ 139)
Typical vs. Atypical
IPAH
p Value
PH-HFpEF
(n ¼ 226)
Typical
IPAH vs. PH-HFpEF
p Value
Atypical
IPAH vs. PH-HFpEF
p Value
Age, yrs 66.6  15.0 61.5  17.3 71.3  9.2 <0.001 73.2  8.3 <0.001 0.434
Female 467 (59.4) 250 (59.4) 77 (55.4%) 1.000 140 (61.9) 1.000 0.686
BMI, kg/m2 28.1 (24.5–32.6) 26.0 (23.3–29.8) 32.2 (28.3–36.0) <0.001 29.6 (25.7–34.0) <0.001 0.002
WHO-FC 0.089 <0.001 0.315
I/II 91 (11.8) 71 (17.4) 12 (8.8) 8 (3.6)
III 540 (70.3) 275 (67.6) 96 (70.6) 169 (75.1)
IV 137 (17.8) 61 (15.0) 28 (20.6) 48 (21.3)
6MWD, m 289.5  121.8 319.0  123.5 250.5  104.2 <0.001 260.0  115.0 <0.001 0.787
RAP, mm Hg 9.8  5.4 8.5  5.2 8.9  4.8 0.615 12.9  4.8 <0.001 <0.001
PAPm, mm Hg 46.0  11.9 46.9  13.3 43.9  10.7 0.025 45.7  9.4 0.437 0.326
PAWP, mm Hg 12.5  6.0 9.3  3.4 10.0  3.6 0.186 19.9  4.4 <0.001 <0.001
TPG, mm Hg 33.5  13.1 37.6  13.6 33.9  11.1 0.006 25.8  9.1 <0.001 <0.001
Cardiac index, l/min/m2 2.2  0.8 2.3  0.8 2.2  0.8 0.629 2.2  0.7 0.653 0.988
PVR, Wood Units 9.6  6.7 10.8  6.0 9.8  10.6 0.309 7.0  3.4 <0.001 <0.001
SvO2, % 62.2  9.0 62.1  9.9 62.7  9.0 0.804 62.1  6.9 0.999 0.863
BNP, pg/ml 269 (127–541) 287 (119–543) 200 (115–469) 1.000 310 (186–638) 0.963 0.312
NT-proBNP, pg/ml 1,738 (621–3,891) 1,435 (541–3,888) 1,683 (478–2,815) 1.000 2,196 (1,125–4,285) 0.021 0.066
Arterial hypertension 66.5 43.2 98.6 <0.001 91.9 <0.001 0.021
CAD 32.0 15.7 59.7 <0.001 46.4 <0.001 0.049
Diabetes mellitus 30.6 10.7 74.8 <0.001 41.2 <0.001 <0.001
AF 28.9 10.7 42.4 <0.001 54.4 <0.001 0.187
BMI >30 kg/m2 37.6 23.5 65.2 <0.001 47.1 <0.001 0.002
Values are mean  SD, n (%), median (interquartile range), or %.
6MWD ¼ 6-min walking distance; AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; CAD ¼ coronary artery disease; HFpEF ¼ heart failure with preserved ejection fraction;
IPAH ¼ idiopathic pulmonary arterial hypertension; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; PAPm ¼ mean pulmonary arterial pressure; PAWP ¼ mean pulmonary artery wedge pressure;
PH ¼ pulmonary hypertension; PVR ¼ pulmonary vascular resistance; RAP ¼ right atrial pressure; SvO2 ¼ mixed venous oxygen saturation; TPG ¼ transpulmonary gradient; WHO-FC ¼ World Health Or-
ganization functional class.
TABLE 2 Targeted PH Therapies
All
Patients
Typical
IPAH
Atypical
IPAH
Typical vs.
Atypical
IPAH
p Value PH-HFpEF
Typical
IPAH vs.
PH-HFpEF
p Value
Atypical
IPAH vs.
PH-HFpEF
p Value
PH treatment initiated within ﬁrst 3 months
n 786 421 139 226
ERA 22.6 31.4 22.3 0.157 6.6 <0.001 <0.001
PDE5i 82.4 76.7 81.3 0.870 93.8 <0.001 0.001
PCA 1.7 2.6 0.7 0.931 0.4 0.197 1.000
2 or more PH drugs 11.7 17.8 7.9 0.013 2.7 <0.001 0.112
Anticoagulation 63.0 56.3 69.8 0.016 71.2 0.001 1.000
PH treatment at 1 year
n 396 207 81 108
ERA 36.4 48.3 35.8 0.195 13.9 <0.001 0.002
PDE5i 80.6 83.6 75.3 0.391 78.7 0.857 1.000
PCA 4.5 5.8 4.9 1.000 1.9 0.452 1.000
2 or more PH drugs 30.6 44.4 25.9 0.014 7.4 <0.001 0.003
Anticoagulation 67.5 62.8 71.6 0.513 73.4 0.184 1.000
Values are %, unless otherwise indicated.
ERA ¼ endothelin receptor antagonist; PCA ¼ prostacyclin analogue; PDE5i ¼ phosphodiesterase type 5 in-
hibitor; other abbreviations as in Table 1.
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Within the small subgroup of patients with PH-
HFpEF receiving an ERA, this treatment was dis-
continued in almost every second patient (43%; p ¼
0.001 vs. typical IPAH), either because of side effects
(23%) or lack of improvement (11%). In patients with
typical IPAH, side effects and lack of improvement
were responsible for ERA discontinuation in 10% and
2%, respectively. Interestingly, patients with atypical
IPAH again fell between these groups, with an ERA
discontinuation rate of 23%.
Treatment discontinuations were associated with
less severe hemodynamics. Patients with typical IPAH
who discontinued pulmonary vasodilator therapy had
lower values for PAPm (risk ratio [RR]: 0.965; 95%
conﬁdence interval [CI]: 0.933 to 0.998; p ¼ 0.039)
and right atrial pressure (RR: 0.885; 95% CI: 0.801 to
0.977; p ¼ 0.016) compared with patients continuing
this therapy. A similar pattern was observed in pa-
tients with PH-HFpEF. Patients who discontinued
PDE5i therapy had lower PAPm (RR: 0.937; 95% CI:
0.897 to 0.979; p ¼ 0.004) and TPG (RR: 0.928; 95%
CI: 0.884 to 0.973; p ¼ 0.002).
RESPONSE TO THERAPY. After PH therapies were
initiated, WHO-FC, exercise capacity, and natriuretic
TABLE 3 Discontinuations of PH Therapies
All Patients
(N ¼ 786)
Typical IPAH
(n ¼ 421)
Atypical IPAH
(n ¼ 139)
Typical vs.
Atypical IPAH
p Value
PH-HFpEF
(n ¼ 226)
Typical IPAH vs.
PH-HFpEF
p Value
Atypical IPAH vs.
PH-HFpEF
p Value
PDE5i ever 696 (88.5) 359 (85.3) 120 (86.3) 1.000 217 (96.0) <0.001 0.003
Patients with follow-up 618 306 106 206
PDE5i discontinuations 79 (12.8) 27 (8.8) 14 (13.2) 0.578 38 (18.4) 0.005 0.795
Side effects 23 (3.7) 8 (2.6) 4 (3.8) 1.000 11 (5.3) 0.454 1.000
Efﬁcacy failure 33 (5.3) 9 (2.9) 3 (2.8) 1.000 21 (10.2) 0.003 0.071
Other* 25 (4.0) 11 (3.6) 7 (6.6) 0.801 7 (3.4) 1.000 0.745
ERA ever 322 (41.0) 225 (53.4) 61 (43.9) 0.188 36 (15.9) <0.001 <0.001
Patients with follow-up 281 190 56 35
ERA discontinuations 56 (19.9) 28 (14.7) 13 (23.2) 0. 462 15 (42.9) 0.001 0.188
Side effects 36 (12.8) 18 (9.5) 10 (17.9) 0.286 8 (22.9) 0.117 1.000
Efﬁcacy failure 9 (3.2) 4 (2.1) 1 (1.8) 1.000 4 (11.4) 0.066 0.210
Other† 11 (3.9) 6 (3.2) 2 (3.6) 1.000 3 (8.6) 0.447 1.000
Values are n (%) or n. *Including switch to riociguat. †Including withdrawal of sitaxentan.
Abbreviations as in Tables 1 and 2.
TABLE 4 Response to Targeted PH Therapy
Typical IPAH Atypical IPAH
Typical vs.
Atypical IPAH
p Value PH-HFpEF
Typical IPAH vs.
PH-HFpEF
p Value
Atypical IPAH vs.
PH-HFpEF
p Value
6MWD, m
Baseline 320 (234 to 417) 250 (175 to 332) <0.001 270 (165 to 345) <0.001 1.000
12 months 414 (324 to 460) 310 (240 to 379) <0.001 330 (194 to 380) <0.001 1.000
Change from baseline
in 6MWD, m
Mean  SD 52  101 58  84 1.000 33  82 0.453 0.904
Median (IQR) 50 (1 to 00) 60 (10 to 75) 29 (10 to 74)
WHO-FC I/II
Baseline 17.4 8.8 0.056 3.6 <0.001 0.164
12 months 39.5 26.2 0.208 23.0 0.026 1.000
Improvement of WHO-FC 34.5 36.9 1.000 36.8 1.000 1.000
Change from baseline
in NT-proBNP/BNP, %
42.6 (77.1 to 17.4) 35.9 (69.9 to 13.8) 1.000 13.7 (40.6 to 32.2) 0.031 0.248
Values are median (interquartile range), mean  SD, or %. Data shown on 6-min walking distance (6MWD) at baseline (on the basis of n ¼ 324 for typical IPAH, n ¼ 105 for
atypical IPAH, and n ¼ 184 for PH-HFpEF), at 12 months (on the basis of n ¼ 126 for typical IPAH, n ¼ 38 for atypical IPAH, and n¼ 46 for PH-HFpEF), and change from baseline
(on the basis of n ¼ 111 for typical IPAH, n ¼ 29 for atypical IPAH, and n ¼ 40 for PH-HFpEF); WHO-FC at baseline (on the basis of n ¼ 407 for typical IPAH, n ¼ 136 for atypical
IPAH, and n ¼ 225 for PH-HFpEF), at 12 months (on the basis of n ¼ 177 for typical IPAH, n ¼ 65 for atypical IPAH, and n ¼ 87 for PH-HFpEF), and % improvement (on the basis
of n ¼ 174 for typical IPAH, n ¼ 65 for atypical IPAH, and n ¼ 87 for PH-HFpEF); and % changes from baseline to 12 months in plasma levels of natriuretic peptide serum levels
(NT-proBNP or BNP, respectively; on the basis of n ¼ 115 for typical IPAH, n ¼ 47 for atypical IPAH, and n ¼ 42 for PH-HFpEF).
Abbreviations as in Table 1.
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peptide levels improved from baseline to 12 months
in all groups, but treatment effects were less pro-
nounced in PH-HFpEF. In all 3 groups, WHO-FC
improved in approximately one-third of the patients
(Table 4). The percentage of patients in WHO-FC I or II
at 12 months was 40% in the typical IPAH group, 26%
in the atypical IPAH group (p ¼ NS vs. typical IPAH),
and 23% in the PH-HFpEF group (p ¼ 0.026 vs. typical
IPAH).
At 1 year, the mean 6MWD increased from baseline
in all groups. Of note, 62% of patients with typical
IPAH, 59% of patients with atypical PAH, and 43% of
those with PH-HFpEF showed an improvement in
6MWD by >30 m.
Natriuretic peptide levels decreased in all groups;
this was most pronounced in patients with typical
IPAH (43% from baseline) and to a lesser extent in
atypical IPAH (36% from baseline) and PH-HFpEF
(14% from baseline).
SURVIVAL. Within the ﬁrst 5 years after initiation of
targeted PH therapy, there was no difference in
overall mortality among the 3 groups (Figure 2).
However, patients with typical IPAH or atypical IPAH
more often died from PH-related complications (56%
and 58%, respectively) compared with patients with
PH-HFpEF (32%; p ¼ 0.026).
DISCUSSION
The current analysis compared disease characteris-
tics, hemodynamics, treatment patterns, response to
therapy, and mortality in patients with IPAH as well
as in patients with PH due to HFpEF, all of whom
received targeted PH therapy. Patients with IPAH
were further subcategorized as typical and atypical,
on the basis of the presence of risk factors for left
heart disease. The risk proﬁles and demographic
characteristics of patients with atypical IPAH resem-
bled those of the PH-HFpEF group, whereas hemo-
dynamics were comparable with typical IPAH. At the
same time, severity of PH, as indicated by a high
PAPm and a low cardiac index, was comparable in all
3 groups; the same was true for survival.
The selection of PH therapies and the evoked
treatment response showed considerable differences
among groups. Although treatment patterns in pa-
tients with typical IPAH were comparable with other
cohorts (20), >90% of the patients with PH-HFpEF
received ﬁrst-line treatment with a PDE5i, whereas
ERAs were rarely used. The therapeutic approach to
atypical IPAH was in between these 2 conditions. The
observed changes in WHO-FC, exercise capacity, and
natriuretic peptide levels indicated some efﬁcacy of
FIGURE 2 5-Year Overall Survival
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There was no signiﬁcant difference in survival among patients with PH who were studied. p1 ¼ p value for typical IPAH versus atypical IPAH; p2 ¼ p value for
typical IPAH versus PH-HFpEF; p3 ¼ p value for atypical IPAH versus PH-HFpEF; other abbreviations as in Figure 1.
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targeted therapies in all 3 populations, with the
greatest improvements seen in patients with typical
IPAH, the least improvements in patients with PH-
HFpEF, and atypical IPAH again in between. With
respect to side effects and tolerability of PH medica-
tions, differences between the 3 groups emerged. In
patients with typical IPAH, side effect proﬁle and
drug tolerability matched data reported from clinical
studies (17). In patients with PH-HFpEF, targeted
therapies, particularly ERAs, were less well tolerated.
Here, the drug discontinuation rate due to side effects
or lack of efﬁcacy reached 34% for ERA and 16% for
PDE5i therapy. In atypical PAH, drug discontinuation
rates were between those of typical IPAH and PH-
HFpEF.
PH in association with left heart disease is arguably
1 of the most common forms of PH. Depending on
methods and deﬁnitions used, the prevalence of PH
in patients with HFpEF has been reported to be as
high as 80% (1). Development of PH or RV dysfunc-
tion in patients with HF carries strong negative
prognostic information (1,4,6). Despite the impor-
tance of PH in HFpEF, the underlying pathomechan-
isms are not entirely clear. Even less clear are the
treatment options; current guidelines discourage the
routine use of targeted PH therapy in patients with
PH-HFpEF but rather emphasize the optimized
treatment of the underlying diseases and comorbid-
ities (10,12).
Our ﬁndings reinforced previous observations that
there is a subpopulation among patients with HFpEF
who have severe PH with a distinct pre-capillary
component (15). Except for the elevated ﬁlling pres-
sures and the resulting lower PVR, the hemodynamic
proﬁles of these patients were similar to what was
found in patients with IPAH. Given the fact that all
patients included in our series had a preserved left
ventricular systolic function, it is likely that the low
cardiac output seen in the patients with PH-HFpEF
resulted primarily from RV rather than left ventricu-
lar dysfunction.
The presence of severe PH together with RV
dysfunction was probably the rationale for the COM-
PERA investigators to prescribe drugs approved for
PAH in patients with PH-HFpEF. According to the
new European Society of Cardiology and European
Respiratory Society guidelines, these patients may be
categorized as having Cpc-PH (8,10). The strong
preference for PDE5i as ﬁrst-line therapy in PH-
HFpEF may have resulted from previous studies of
ERA and PDE5i in heart failure patients with reduced
(21–24) and preserved ejection fraction (25). So far,
almost all trials with ERA in patients with left heart
disease failed to show clinical beneﬁt and were
associated with frequent side effects, predominantly
ﬂuid retention (26). The high discontinuation rate for
ERA in our PH-HFpEF group was in line with these
observations.
In contrast to ERA, there have been promising pre-
clinical and clinical data for PDE5i in patients with
PH-HFpEF, including a small positive randomized
controlled trial (23,25). The largest study on the use of
sildenaﬁl in 216 patients with HFpEF, however, did
not show improvement of exercise capacity or
symptoms compared with placebo, but this study did
not speciﬁcally include patients with PH-HFpEF (27).
A recent single-center randomized clinical trial
showed no efﬁcacy of sildenaﬁl in improving pul-
monary hemodynamics or exercise capacity in 52
patients with HFpEF and predominantly post-
capillary PH (28).
Our data indicated that PDE5i therapy was gener-
ally well-tolerated with comparable side effect pro-
ﬁles in patients with typical and atypical IPAH as well
as in patients with PH-HFpEF. With respect to treat-
ment efﬁcacy, our results should be interpreted with
particular caution. Improvements in 6MWD, WHO-
FC, and natriuretic peptide levels were observed,
although the changes were more pronounced with
typical IPAH as compared with PH-HFpEF, whereas
the responses in patients with atypical IPAH were in-
between. Although efﬁcacy failure led to treatment
discontinuation in <3% of the patients with typical or
atypical IPAH, this lack of improvement caused
withdrawal of the PDE5i in 10% of the patients with
PH-HFpEF. It is tempting to speculate that the
declining contribution of a pre-capillary component
of PH, as well as the increasing frequency of comor-
bidities from typical IPAH to atypical IPAH and PH-
HFpEF, attenuated the treatment response of these
patients with respect to PAH-targeted drugs. Char-
alampopoulos et al. (15) recently reported data sup-
porting this concept. This would also explain the
putative discrepancy between our patients with PH-
HFpEF having a mean PVR of 7 WU and the previ-
ous reports mentioned earlier, which provided either
no resistance data (2,27) or a median PVR of 2.6 WU
(28).
The survival curves in the 3 patient populations
studied herein were almost superimposable. In the
ASPIRE (Assessing the Spectrum of Pulmonary Hy-
pertension Identiﬁed at a Referral Centre) registry
(20), patients with PH-HFpEF had a 3-year-survival
rate >80%, compared with 62% in our series. In
contrast to our patients, patients with PH-HFpEF in
ASPIRE had lower PVR values and normal cardiac
output. It is conceivable that our patients’ more
severe PH contributed to their higher mortality.
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This notion was supported by the fact that PH and
right heart failure were listed as cause of death in 32%
of the patients with PH-HFpEF in our series.
Our data supported the hypothesis that there may
be a disease continuum ranging from typical IPAH
through atypical IPAH to PH-HFpEF (Central
Illustration). As in many other ﬁelds of medicine,
clinical classiﬁcations were introduced to clarify
complex biological systems, but often single cut-off
values failed to separate disease entities, especially
in multifactorial diseases and in aging patient pop-
ulations (13). The hemodynamic separation of pre-
from post-capillary PH by the PAWP threshold of
15 mm Hg might be such an example. On the basis of
data presented here, it is most likely that a number
of our patients have been labeled as IPAH despite the
presence of several risk factors (as deﬁned earlier)
predisposing for the development of post-capillary
PH. In the AMBITION trial, this phenomenon was
observed during the early enrollment period, which
led to modiﬁcation of the inclusion criteria prevent-
ing further enrollment of patients with 3 or more risk
factors for left heart disease, that is, atypical IPAH
(16,17). Interestingly, the analysis of the 2 groups
(“original” vs. “restricted” inclusion criteria) sup-
ported our ﬁndings, as it described a similar shift in
age and comorbidity proﬁle with comparable hemo-
dynamics. As in our study, patients with atypical
IPAH in the AMBITION trial did respond to PH ther-
apies, although the response was attenuated and the
rate of treatment discontinuations was higher (17).
STUDY LIMITATIONS. Our study had both strengths
and limitations. Strengths included the large sample
size of prospectively enrolled patients with newly
CENTRAL ILLUSTRATION Pulmonary Hypertension in Typical PAH, Atypical PAH, and HFpEF
Opitz, C.F. et al. J Am Coll Cardiol. 2016;68(4):368–78.
Various factors and comorbidities appear more or less frequently in patients with typical idiopathic pulmonary arterial hypertension (IPAH), deﬁned as <3 risk factors for
left heart disease; in patients with atypical IPAH ($3 risk factors); and in patients with PH–heart failure with preserved ejection fraction (HFpEF). Given the patterns and
tendencies seen, is there a disease continuum ranging from typical IPAH through atypical IPAH to PH-HFpEF? AF ¼ atrial ﬁbrillation; CAD ¼ coronary artery disease;
DPG ¼ diastolic pressure gradient; PAH ¼ pulmonary arterial hypertension; PVR ¼ pulmonary vascular resistance; TPG ¼ transpulmonary pressure gradient.
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diagnosed, incident PH; the relatively long observa-
tion period; the low number of patients who were lost
to follow-up; the “real-life” setting; and the avail-
ability of hemodynamic data from right heart cathe-
terization at the time of diagnosis. Limitations
included the registry nature of the data source, which
obviously does not reach the quality of a randomized
clinical trial. Hence, any data on drug effects must be
interpreted with great caution. However, the COM-
PERA registry enrolls consecutive patients on a pro-
spective basis, and several control measures have
been implemented to ensure high data quality,
including independent on-site source data moni-
toring. Nevertheless, comorbidities were only docu-
mented as far as they are known to be associated with
the development of left heart disease and/or PH.
Medications other than PAH-approved drugs and an-
ticoagulants were not documented. Complete follow-
up data were not available for all parameters, and
systematic echocardiographic or hemodynamic
follow-up data were lacking. Further, we did not
apply statistical measures to reduce confounding
(such as propensity-score matching or multivariable
risk-adjusted modeling), and thus, for all results and
conclusions it must be considered that groups
differed in many respects at baseline. Finally, the
sample of patients with PH-HFpEF described herein
represented a unique subset of patients with severe
PH and HFpEF who were judged as candidates for
targeted PH therapies by the expert COMPERA in-
vestigators on an individual basis. Therefore, our
ﬁndings are not generalizable to all patients with
PH-HFpEF and should not promote uncritical and
potentially dangerous use of PAH drugs in this group
of patients. In addition, the elevated right atrial
pressure in the PH-HFpEF group might be an indica-
tor that the therapeutic potential of optimized vol-
ume control (29) has not fully been utilized by the
COMPERA investigators.
CONCLUSIONS
Our ﬁndings underscored the notion that there is a
population of patients with risk factors for left heart
disease presenting with pre-capillary PH that is
characterized by disease features lying in between
typical IPAH and PH-HFpEF. Our data, in line with
recent reports from the AMBITION study (16,17) and
others (15), indicated that these patients beneﬁt from
PH-targeted therapies, albeit to a lesser extent than
patients with typical IPAH. In addition, our results
also indicated potential beneﬁts of PH-targeted
therapies in patients with HFpEF and with com-
bined pre- and post-capillary PH. As patients with
atypical IPAH and PH-HFpEF are becoming more
common, future studies should aim to identify the
most appropriate treatment strategies for these pa-
tient populations.
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